A strategic area of expertise for Ceva, canine cardiology has benefited from substantial R&D investment.

strategic area of expertise for Ceva, canine cardiology has benefited from substantial R&D investment. Among other things, this investment has allowed the Group to develop, for the very first time in veterinary medicine, a molecule that was previously restricted to use in human cardiology: spironolactone.


With PRILACTONE®, vets now have a new, high-performing treatment for heart failure.

The European public assessment report on the product concludes:

"PRILACTONE is used to treat dogs that have congestive heart failure because of faulty heart valves. When the heart valves are faulty, the heart is not able to pump blood as efficiently as before. As a result, blood can accumulate in the veins and fluid can leak out into the tissues, leading to the heart being unable to deliver oxygen-rich blood to the body adequately. PRILACTONE® is used in combination with “standard therapy” (other heart medicines, including diuretic support where necessary).

PRILACTONE® is given to the dog once daily, with food (either mixed in the food, or immediately after feeding). The dose to use is 2 mg per kilogram of the dog’s body weight. The appropriate number of tablets, half tablets or quarter tablets to give according to the dog’s size is given in the Package Leaflet.

How does PRILACTONE® work?

The active substance in PRILACTONE®, spironolactone, blocks the actions of a hormone called aldosterone in the kidneys, heart and blood vessels. By blocking aldosterone, spironolactone causes the kidneys to excrete salt and fluids, but retain potassium, and hence it improves heart function. It is accepted there are also other ways in which spironolactone works on the heart and blood vessels in congestive heart failure (although these mechanisms of action have not yet been fully demonstrated in dogs).

How has PRILACTONE® been studied?

PRILACTONE® has been studied in the laboratory, as well as in three studies in dogs with heart valve diseases, which were treated in various veterinary practices or clinics across Europe (‘clinical studies‘). In these clinical studies, the animal owners gave either PRILACTONE® tablets or placebo (dummy tablets without any active ingredient) to their dogs, once daily, at a dose of 2 mg/kg with food. PRILACTONE® tablets were given with food because this results in more of the active substance being absorbed from the tablets. All dogs also received ‘standard therapy’ (generally another medicine belonging to the group called ACE-inhibitors and if needed a diuretic). Treatment continued for up to 15 months.

What benefit has PRILACTONE® shown during the studies?

The results of the studies showed that dogs with congestive heart failure caused by faulty heart valves that were given PRILACTONE® tablets in addition to another heart medicine (‘standard therapy’), had a longer survival time than the dogs that received the standard therapy plus placebo tablets. In a long term study, the dogs treated with PRILACTONE® also showed less deterioration of their heart disease compared to the dogs which were treated only with ‘standard therapy’.

  • PRILENAL® (enalapril)

PRILENAL® is a standard therapy to treat heart failure. It is widely recognised and used in veterinary medicine and perfectly complements the PRILACTONE® heart failure treatment. PRILENAL® is used to treat early, moderate or severe congestive heart failure caused by mitral regurgitation or dilated cardiomyopathy, and is a complement to diuretics (furosemide with or without digitalis such as digoxin).

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top